207 related articles for article (PubMed ID: 24038885)
21. Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand.
Bhurani D; Schifter M; Kerridge I
Bone Marrow Transplant; 2008 Oct; 42(8):547-50. PubMed ID: 18622418
[TBL] [Abstract][Full Text] [Related]
22. The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review.
Van der Beek JN; Oosterom N; Pieters R; de Jonge R; van den Heuvel-Eibrink MM; Heil SG
Crit Rev Oncol Hematol; 2019 Oct; 142():1-8. PubMed ID: 31323533
[TBL] [Abstract][Full Text] [Related]
23. [Clinical evaluation of severe toxicity in two patients with acute lymphoblastic leukemia receiving outpatient methotrexate therapy].
Hatae Y; Hatayama Y; Nishi M; Murakami T; Nobumoto K; Nakadate H; Iizuka S; Takeda T; Wada I
Rinsho Ketsueki; 1991 Nov; 32(11):1503-8. PubMed ID: 1758061
[TBL] [Abstract][Full Text] [Related]
24. Complications of tumour overkill when associated with high dose methotrexate therapy.
Bell R; Forbes IK; Sullivan JR; Hurley TH
Clin Exp Pharmacol Physiol Suppl; 1979; 5():47-55. PubMed ID: 400971
[TBL] [Abstract][Full Text] [Related]
25. High-dose methotrexate with folinic acid rescue.
Bender JF; Grove WR; Fortner CL
Am J Hosp Pharm; 1977 Sep; 34(9):961-5. PubMed ID: 333910
[TBL] [Abstract][Full Text] [Related]
26. Nephrotoxicity due to intermediate-dose methotrexate without rescue in an obese adolescent with acute lymphoblastic leukemia.
Sauer M; Rydholm N; Piatkowski J; Lewis V; Steiner M
Pediatr Hematol Oncol; 2002 Mar; 19(2):135-40. PubMed ID: 11881788
[TBL] [Abstract][Full Text] [Related]
27. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
28. Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation.
Cohen IJ
Med Hypotheses; 2007; 68(5):1147-53. PubMed ID: 17270361
[TBL] [Abstract][Full Text] [Related]
29. [Leucovorin rescue after continuing infusion of high dose methotrexate].
Yang LH; Lu XT; Gu J; Hua Y; Zhao WH
Zhonghua Er Ke Za Zhi; 2005 May; 43(5):393-4. PubMed ID: 15924763
[No Abstract] [Full Text] [Related]
30. Successful treatment of intrathecal methotrexate overdose with folinic acid rescue: a case report.
Riva L; Conter V; Rizzari C; Jankovic M; Sala A; Milani M
Acta Paediatr; 1999 Jul; 88(7):780-2. PubMed ID: 10447141
[TBL] [Abstract][Full Text] [Related]
31. Folinic acid administration following MTX as prophylaxis for GVHD.
Gratwohl A
Bone Marrow Transplant; 2009 Aug; 44(4):257. PubMed ID: 19204714
[No Abstract] [Full Text] [Related]
32. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis.
Buckley LM; Vacek PM; Cooper SM
J Rheumatol; 1990 Sep; 17(9):1158-61. PubMed ID: 2132565
[TBL] [Abstract][Full Text] [Related]
33. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
[TBL] [Abstract][Full Text] [Related]
34. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
[TBL] [Abstract][Full Text] [Related]
35. Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate.
Fan CM; Foster BK; Hui SK; Xian CJ
PLoS One; 2012; 7(10):e46915. PubMed ID: 23071661
[TBL] [Abstract][Full Text] [Related]
36. [High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children].
Makhonova LA; Maiakova SA; Kiselev AV; Gordina GA; Balakirev SA; Gavrilova IE; Moiseenko EI; Morozova OV
Vopr Onkol; 1990; 36(10):1196-200. PubMed ID: 2251813
[TBL] [Abstract][Full Text] [Related]
37. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment.
Fan C; Cool JC; Scherer MA; Foster BK; Shandala T; Tapp H; Xian CJ
Bone; 2009 Jan; 44(1):61-70. PubMed ID: 18976724
[TBL] [Abstract][Full Text] [Related]
38. How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?
Cansu DÜ; Teke HÜ; Bodakçi E; Korkmaz C
Clin Rheumatol; 2018 Dec; 37(12):3419-3425. PubMed ID: 30056523
[TBL] [Abstract][Full Text] [Related]
39. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Cohen IJ
Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
[TBL] [Abstract][Full Text] [Related]
40. [Moderate dose methotrexate with citrovorum factor rescue therapy in the treatment of head and neck cancer].
Inuyama Y; Hiroto I; Taketa C; Horiuchi M; Mashino S; Fujii M; Matsuura S; Satake B; Takeoda S; Nishijima W; Okuda M; Sakaguchi K; Tanigaito Y; Imakirei M; Konno T; Hirokawa T; Takada K; Ono I; Saitoh H; Takemiya S; Shimada F; Omura K; Miyake H; Fujii K; Kawabe Y; Kondoh T; Komiyama S; Yanagida T; Matsumura Y; Hirano M; Araki S
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2193-200. PubMed ID: 6764099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
